Takeda Looks To Double Emerging Market Revenues
Focus Will Be On Innovation
Executive Summary
Japanese firm aims for growth ahead of the market as it rolls out global innovative products and its Wave 1 portfolio across emerging markets, aided by "targeted investments".
You may also be interested in...
Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition
Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.
Takeda Looks To Ride 'Wave 1' To JPY5tn Target
Takeda tries to get investors as excited as it is about the first wave of post-R&D reorganization candidates coming through, as it lays out 'ambitious but achievable' revenue target.
New Deals, Modalities In Sights In Japan After Relatively Quiet 2022
After a comparatively subdued 2022 in terms of M&A and other deal-making, a strengthening currency and interest in new areas such as digital tools and cell and gene therapy might see a rebound in activity this year, which should also see domestic approvals of several potential blockbusters and more support for bioventures.